MAIA Quote, Financials, Valuation and Earnings

Emergent BioSolutions has a net margin of -- compared to MAIA Biotechnology's net margin of 40.45%. MAIA Biotechnology's return on equity of -- beat Emergent BioSolutions's return on equity of -35.94%.

MAIA Biotechnology has a consensus price target of $12.63, signalling upside risk potential of 504.07%. On the other hand Emergent BioSolutions has an analysts' consensus of $12.00 which suggests that it could grow by 45.1%. Given that MAIA Biotechnology has higher upside potential than Emergent BioSolutions, analysts believe MAIA Biotechnology is more attractive than Emergent BioSolutions.

MAIA Biotechnology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Emergent BioSolutions has a beta of 1.594, suggesting its more volatile than the S&P 500 by 59.352%.

MAIA Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Emergent BioSolutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MAIA Biotechnology pays -- of its earnings as a dividend. Emergent BioSolutions pays out -- of its earnings as a dividend.

MAIA Biotechnology quarterly revenues are --, which are smaller than Emergent BioSolutions quarterly revenues of $283.8M. MAIA Biotechnology's net income of -$2.7M is lower than Emergent BioSolutions's net income of $114.8M. Notably, MAIA Biotechnology's price-to-earnings ratio is -- while Emergent BioSolutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MAIA Biotechnology is -- versus 0.40x for Emergent BioSolutions. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to MAIA Biotechnology's net margin of -49.65%. MAIA Biotechnology's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

MAIA Biotechnology has a consensus price target of $12.63, signalling upside risk potential of 504.07%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 546.03%. Given that NovaBay Pharmaceuticals has higher upside potential than MAIA Biotechnology, analysts believe NovaBay Pharmaceuticals is more attractive than MAIA Biotechnology.

MAIA Biotechnology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

MAIA Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MAIA Biotechnology pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

MAIA Biotechnology quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. MAIA Biotechnology's net income of -$2.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, MAIA Biotechnology's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MAIA Biotechnology is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to MAIA Biotechnology's net margin of -2357.27%. MAIA Biotechnology's return on equity of -- beat Palatin Technologies's return on equity of --.

MAIA Biotechnology has a consensus price target of $12.63, signalling upside risk potential of 504.07%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1431.53%. Given that Palatin Technologies has higher upside potential than MAIA Biotechnology, analysts believe Palatin Technologies is more attractive than MAIA Biotechnology.

MAIA Biotechnology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

MAIA Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MAIA Biotechnology pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

MAIA Biotechnology quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. MAIA Biotechnology's net income of -$2.7M is higher than Palatin Technologies's net income of -$7.8M. Notably, MAIA Biotechnology's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MAIA Biotechnology is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -- compared to MAIA Biotechnology's net margin of 36.03%. MAIA Biotechnology's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 17.19%.

MAIA Biotechnology has a consensus price target of $12.63, signalling upside risk potential of 504.07%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 47.82%. Given that MAIA Biotechnology has higher upside potential than Regeneron Pharmaceuticals, analysts believe MAIA Biotechnology is more attractive than Regeneron Pharmaceuticals.

MAIA Biotechnology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

MAIA Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MAIA Biotechnology pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

MAIA Biotechnology quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. MAIA Biotechnology's net income of -$2.7M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, MAIA Biotechnology's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MAIA Biotechnology is -- versus 5.92x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.